Literature DB >> 9613715

Oxidative mechanisms in nigral cell death in Parkinson's disease.

P Jenner1.   

Abstract

Oxidative stress may contribute to nigral cell death in Parkinson's disease based on postmortem investigations showing increased iron levels, decreased levels of reduced glutathione (GSH), and impaired mitochondrial function. This leads to oxidative damage because lipid peroxidation is increased in substantia nigra and there is a widespread increase in protein and DNA oxidation in the brain in Parkinson's disease. Nitric oxide (NO) may be one of the free radical species involved in nigral degeneration. NO is involved in the production of hydroxyl radicals resulting from MPP+-induced dopamine efflux in striatum. Mice treated with the neuronal nitric oxide synthase (NOS) inhibitor 7-nitroindazole show reduced toxicity to MPTP and knock-out mice lacking neuronal NOS show decreased MPTP susceptibility. In primates, 7-nitroindazole inhibits MPTP toxicity but this remains controversial because no protection is afforded by the nonspecific NOS inhibitor, L-NAME. Indeed, in Parkinson's disease itself, there is little evidence for nitric oxide's involvement in nigral pathology. A susceptibility factor for the development of Parkinson's disease may involve isoforms of cytochrome P450, some of which are found in the brain. CYP2EI, which is associated with free radical production and the formation of endogenous toxins, is selectively localized in nigral dopamine-containing cells. CYP2E1 metabolizes n-hexane leading to the formation of its neurotoxic metabolite 2,5-hexanedione which may explain cases of solvent-induced parkinsonism. Oxidative processes clearly contribute to the pathology of Parkinson's disease but are probably secondary to some other primary unidentified cause, presumably genetic or environmental. Nevertheless, their involvement may allow therapeutic intervention in the cascade of events associated with the progression of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9613715

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  94 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

2.  Nuclear translocation of anamorsin during drug-induced dopaminergic neurodegeneration in culture and in rat brain.

Authors:  Kyung-Ah Park; Nuri Yun; Dong-Ik Shin; So Yoen Choi; Hyun Kim; Won-Ki Kim; Yuzuru Kanakura; Hirohiko Shibayama; Young J Oh
Journal:  J Neural Transm (Vienna)       Date:  2010-10-06       Impact factor: 3.575

3.  Inhibition of rat brain microsomal cytochrome P450-dependent dealkylation activities by an oxidative stress.

Authors:  P Lagrange; R D El-Bachá; P Netter; A Minn
Journal:  Neurotox Res       Date:  2001-08       Impact factor: 3.911

Review 4.  The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine.

Authors:  Hermann M Bolt; Peter H Roos; Ricarda Thier
Journal:  Int Arch Occup Environ Health       Date:  2003-03-01       Impact factor: 3.015

5.  Manganese potentiates LPS-induced heme-oxygenase 1 in microglia but not dopaminergic cells: role in controlling microglial hydrogen peroxide and inflammatory cytokine output.

Authors:  Celia A Dodd; Nikolay M Filipov
Journal:  Neurotoxicology       Date:  2011-09-25       Impact factor: 4.294

6.  Inflammatory effects of highly pathogenic H5N1 influenza virus infection in the CNS of mice.

Authors:  Haeman Jang; David Boltz; Jennifer McClaren; Amar K Pani; Michelle Smeyne; Ane Korff; Robert Webster; Richard Jay Smeyne
Journal:  J Neurosci       Date:  2012-02-01       Impact factor: 6.167

7.  PGE2 EP1 receptor deletion attenuates 6-OHDA-induced Parkinsonism in mice: old switch, new target.

Authors:  Abdullah Shafique Ahmad; Takayuki Maruyama; Shuh Narumiya; Sylvain Doré
Journal:  Neurotox Res       Date:  2013-02-06       Impact factor: 3.911

8.  Inhibition of vesicular monoamine transporter-2 activity in alpha-synuclein stably transfected SH-SY5Y cells.

Authors:  Jun Tang Guo; An Qi Chen; Qi Kong; Hua Zhu; Chun Mei Ma; Chuan Qin
Journal:  Cell Mol Neurobiol       Date:  2007-11-06       Impact factor: 5.046

9.  Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson's disease.

Authors:  Eliseu Felippe dos Santos; Estela Natacha Brandt Busanello; Anelise Miglioranza; Angela Zanatta; Alethea Gatto Barchak; Carmen Regla Vargas; Jonas Saute; Charles Rosa; Maria Júlia Carrion; Daiane Camargo; André Dalbem; Jaderson Costa da Costa; Sandro René Pinto de Sousa Miguel; Carlos Roberto de Mello Rieder; Moacir Wajner
Journal:  Metab Brain Dis       Date:  2009-03-18       Impact factor: 3.584

10.  An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.

Authors:  Todd B Sherer; Ranjita Betarbet; Amy K Stout; Serena Lund; Melisa Baptista; Alexander V Panov; Mark R Cookson; J Timothy Greenamyre
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.